Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Disposal

15 Feb 2005 14:32

Infast Group PLC15 February 2005 EXIT FROM MANUFACTURING COMPLETED Infast Group plc ("Infast" or the "Company") announces that today it completed amajor part of its strategic programme, announced in July 2004, with the sale ofthe assets and business of Infast Philidas Limited ("Philidas" or the"business"). The withdrawal from all manufacturing operations has been achieved: • At a financial impact less than expected in July 2004. The exceptional charge excluding goodwill realisation is expected to be around £7 million (pre-tax relief) compared to the £8 million announced in July 2004. • Earlier than previously expected. • Primarily by sale rather than closure. • Without impacting the availability of product to Infast's core services divisions. Graham Titcombe, Chairman of Infast said: "Having exited from manufacturing,Infast is now positioned to focus fully on its value added Inventory Managementbusinesses, which are located in Europe and North America. "Further, the property disposals relating to our exit from manufacturing arecurrently underway. The sale of these properties will generate significantadditional cash flow in 2005. This will be used to reduce the Company's debt." Disposal of Philidas Philidas, which is located at Pontefract in West Yorkshire, is a producer ofmetal fasteners. In the year ended 31 December 2004, the business had turnover of £7.9 millionand made a trading loss of £0.8 million. Under the terms of the sale, the purchaser will acquire the net trading assetsof the business for an initial cash consideration of £0.4 million, plus deferredconsideration, estimated to be £0.3 million, payable as product is supplied toInfast. Debt due to Philidas for goods recently supplied will not pass to thepurchaser. This is estimated to be a further £0.9 million, representing anadditional cash flow benefit to Infast. The book value of the net assets of thebusiness being sold is approximately £2.9 million. The purchaser has undertaken all employment and lease liabilities of Philidas. For further information, please contact Infast Group plc Tel: 01452 880 500Robert Sternick, Chief ExecutiveJohn Kimber, Finance Director Rawlings Financial PR Limited Tel: 01756 770 376John RawlingsCatriona Valentine This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th May 20237:00 amRNSTransfer of ToxHub Platform and launch of Centrus®
11th May 20233:26 pmRNSHolding(s) in Company
11th May 20237:00 amRNSUS Government Contract Award
4th May 20235:07 pmRNSHolding(s) in Company
3rd May 20237:00 amRNSNotice of Results and Investor Presentation
2nd May 20234:13 pmRNSExercise of Options, Issue of Equity & TVR
14th Apr 20234:38 pmRNSHolding(s) in Company
13th Mar 20237:30 amRNSNo Exposure to Silicon Valley Bank
31st Jan 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSAppointment of Independent Non-Executive Director
5th Jan 20237:00 amRNSExercise of Options, Director/PDMR Dealing & TVR
22nd Dec 20227:00 amRNSContract Extension with Leading CRO
30th Nov 20225:48 pmRNSHolding(s) in Company
12th Oct 20227:00 amRNSExercise of Options, Issue of Equity and TVR
27th Sep 20227:01 amRNSHalf-year Report
27th Sep 20227:00 amRNSSettlement of Historical Licence Dispute
13th Sep 20227:00 amRNSNotice of Results and Investor Presentation
9th Sep 20223:49 pmRNSHolding(s) in Company
2nd Sep 20227:00 amRNS$12m five-year agreement with Leading CRO
4th Aug 20227:00 amRNSHalf Year Trading Update
29th Jun 20225:03 pmRNSHolding(s) in Company
9th Jun 20224:01 pmRNSResult of AGM
20th May 20224:31 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of AGM & Posting of Annual Report
3rd May 202212:00 pmRNSHolding(s) in Company
3rd May 20227:00 amRNSEuropean Medicines Agency Research Grant
26th Apr 20224:40 pmRNSSecond Price Monitoring Extn
26th Apr 20224:35 pmRNSPrice Monitoring Extension
26th Apr 202210:15 amRNSEarn Outs and Deferred Payments
26th Apr 20229:54 amRNSFinal Results
26th Apr 20227:00 amRNSAnnouncement re: full year results
20th Apr 20229:05 amRNSNotice of Results & Investor Presentation
15th Mar 20221:49 pmRNSGrant of PDMR Options
14th Mar 20225:29 pmRNSExercise of Options, Issue of Equity and TVR
14th Mar 202211:22 amRNSHolding(s) in Company
22nd Feb 202210:15 amRNSHolding(s) in Company
4th Feb 20228:08 amRNSDirector/PDMR Shareholding
26th Jan 20227:00 amRNSTrading Update
11th Jan 20227:00 amRNSAppointment of Joint Broker
21st Dec 20217:00 amRNSH2 China Market Update
13th Dec 20214:55 pmRNSHolding(s) in Company
22nd Nov 20212:33 pmRNSHolding(s) in Company
22nd Nov 20217:00 amRNSNew In Silico Software Release
11th Oct 20213:15 pmRNSDirector/PDMR Shareholding
29th Sep 202110:34 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSDirectorate Change
28th Sep 20217:00 amRNSGrant of PDMR Options
27th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSNotice of Results and Investor Presentation
14th Sep 20217:00 amRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.